|
Pasteurella Infections
|
C01.150.252.400.700.662 |
|
|
Tetraethylammonium
|
D02.092.877.787.500 |
|
|
Tetraethylammonium Compounds
|
D02.092.877.787 |
|
|
Attention Deficit and Disruptive Behavior Disorders
|
F03.625.094 |
|
|
ATP Binding Cassette Transporter 1
|
D12.776.395.550.020.381.500 |
|
|
Calcium Fluoride
|
D01.146.325 |
|
|
MAP Kinase Kinase 5
|
D12.776.476.440.500 |
|
|
Togaviridae Infections
|
C01.925.782.930 |
|
|
RNA Virus Infections
|
C01.925.782 |
|
|
Tonsillar Neoplasms
|
C04.588.443.665.710.684.800 |
|
|
Oropharyngeal Neoplasms
|
C04.588.443.665.710.684 |
|
|
Aphasia, Primary Progressive
|
C23.888.592.604.150.500.800.100.155 |
|
|
Aphasia
|
C23.888.592.604.150.500.800.100 |
|
|
Double Effect Principle
|
K01.752.566.479.101 |
|
|
Self-Testing
|
I03.733 |
|
|
Amacrine Cells
|
A11.671.650.850.500 |
|
|
Ledum
|
B01.650.940.800.575.912.250.341.937.324 |
|
|
Blotting, Western
|
E05.601.470.320.200 |
|
|
Immunoblotting
|
E05.601.470.320 |
|
|
Alexander Disease
|
C16.320.565.189.362.312 |
|
